ClinicalTrials.gg

Program

trastuzumab deruxtecan

Also written as “Trastuzumab deruxtecan”, “Trastuzumab Deruxtecan” and “DS-8201a”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms, led by 4 companies.

Furthest: phase 4, since Apr 13, 201849 company-led studies, 31 open or runningNext primary completion: Feb 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyo2611 open or runningphase 3since Apr 13, 2018Sep 21, 2015Oct 1, 2027phase 3 · NCT05950945
AstraZeneca2120 open or runningphase 4since May 21, 2024Sep 22, 2017Feb 10, 2027phase 2 · NCT06271837
Pfizer10 open or runningphase 2since Aug 31, 2020Aug 31, 2020none ahead
Strata Oncology10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Parexel, Merck, Bristol-Myers Squibb and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 37 studies since Sep 21, 2015.

  1. Jan 19, 2024Phase 2 study in Breast NeoplasmsAstraZeneca · NCT06271837 · 127 enrolled · China
  2. May 21, 2024Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT06467357 · 620 planned · United States, Australia, Austria and more
  3. May 21, 2024Phase 4 study in Breast NeoplasmsAstraZeneca · NCT06429761 · 100 enrolled · India
  4. Dec 9, 2024Phase 3 study in Stomach NeoplasmsDaiichi Sankyo · NCT06731478 · 726 planned · United States, Argentina, Australia and more
  5. Dec 12, 2024Phase 3 study in HER2-positive Gastric CancerAstraZeneca · NCT06764875 · 840 planned · United States, Argentina, Australia and more
  6. Feb 5, 2025Phase 3 study in Ovarian NeoplasmsDaiichi Sankyo · NCT06819007 · 582 planned · United States, Australia, Austria and more
  7. Mar 11, 2025Phase 3 study in Endometrial NeoplasmsAstraZeneca · NCT06989112 · 600 planned · United States, Australia, Austria and more
  8. Mar 21, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungDaiichi Sankyo · NCT06899126 · 686 planned · United States, Argentina, Belgium and more
  9. Jun 3, 2025Phase 1 study in RecurrenceDaiichi Sankyo · NCT07015697 · 76 planned · United States, Brazil, France and more
  10. Jun 6, 2025Phase 3 study in Endometrial NeoplasmsDaiichi Sankyo · NCT07022483 · 710 planned · United States, Argentina, Chile and more
  11. Jun 24, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712 · 100 planned · United States, Canada, China and more
  12. Jun 25, 2026Phase 3 study in Breast NeoplasmsDaiichi Sankyo · NCT07683754 · 200 planned · United States
  13. Oct 22, 2026Primary completion moved from 2026-11-11 to 2027-05-03Date moved laterphase 3 · +6 months · NCT04784715
  14. Oct 26, 2026Primary completion moved from 2026-08-03 to 2028-02-17Date moved laterphase 3 · +18 months · NCT06174987

Ahead

  1. Feb 10, 2027Primary completion: phase 2 study in Breast NeoplasmsAstraZeneca · NCT06271837
  2. Mar 23, 2027Primary completion: phase 2 study in Pancreatic NeoplasmsAstraZeneca · NCT04482309
  3. May 3, 2027Primary completion: phase 3 study in Breast NeoplasmsAstraZeneca · NCT04784715
  4. May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT04379596

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 binding agent”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 49 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07683754Breast Neoplasms · United States3RecruitingDaiichi SankyoJul 4, 2030200
NCT07069712Stomach Neoplasms · United States, Canada, China and more2RecruitingAstraZenecaNov 9, 2027100
NCT07022483Endometrial Neoplasms · United States, Argentina, Chile and more3RecruitingDaiichi SankyoFeb 26, 2030710
NCT07015697Recurrence · United States, Brazil, France and more1RecruitingDaiichi SankyoDec 31, 202876
NCT06899126Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3RecruitingDaiichi SankyoApr 24, 2030686
NCT06989112Endometrial Neoplasms · United States, Australia, Austria and more3RecruitingAstraZenecaJan 19, 2029600
NCT06819007Ovarian Neoplasms · United States, Australia, Austria and more3RecruitingDaiichi SankyoNov 1, 2028582
NCT06764875HER2-positive Gastric Cancer · United States, Argentina, Australia and more3RecruitingAstraZenecaApr 27, 2029840
NCT06731478Stomach Neoplasms · United States, Argentina, Australia and more3RecruitingDaiichi SankyoJun 1, 2028726
NCT06467357Biliary Tract Neoplasms · United States, Australia, Austria and more3RecruitingAstraZenecaJun 12, 2028620
NCT06429761Breast Neoplasms · India4Active, not recruitingAstraZenecaOct 31, 2026100
NCT06271837Breast Neoplasms · China2Active, not recruitingAstraZenecaFeb 10, 2027127
NCT06174987Neoplasm Metastasis · United States, Australia, Brazil and more3RecruitingDaiichi SankyoFeb 17, 202875
NCT05950945Breast Neoplasms · United States, Australia, Belgium and more3RecruitingDaiichi SankyoOct 1, 2027250
NCT05246514HER2-mutant Non-Small Cell Lung Cancer · China2Active, not recruitingAstraZenecaNov 4, 202472
NCT05113251Breast Neoplasms · United States, Brazil, Bulgaria and more3Active, not recruitingAstraZenecaMar 12, 2025927
NCT05097599Neoplasms · United States2TerminatedStrata OncologyJun 12, 202411
NCT05048797Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more3Active, not recruitingAstraZenecaJun 9, 2026454
NCT04989816Adenocarcinoma · China2CompletedAstraZenecaJun 16, 202395
NCT04784715Breast Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingAstraZenecaMay 3, 20271,157
NCT04739761Breast Neoplasms · United States, Australia, Belgium and more3Active, not recruitingAstraZenecaFeb 8, 2024506
NCT04744831Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedDaiichi SankyoNov 1, 2022122
NCT04704934Stomach Neoplasms · Argentina, Belgium, Brazil and more3Active, not recruitingDaiichi SankyoAug 31, 2026490
NCT04686305Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more1RecruitingAstraZenecaJun 30, 2027304
NCT04644237Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2CompletedDaiichi SankyoDec 23, 2022152
NCT04622319HER2-Positive Primary Breast Cancer · United States, Argentina, Australia and more3Active, not recruitingDaiichi SankyoJul 2, 20251,600
NCT04639219Neoplasm Metastasis · United States, Belgium, Canada and more2Active, not recruitingAstraZenecaJan 25, 2023102
NCT04556773Breast Neoplasms · United States, Australia, Belgium and more1Active, not recruitingAstraZenecaAug 16, 2023138
NCT04539938Breast Neoplasms · United States2CompletedPfizerJul 15, 202470
NCT04538742Breast Neoplasms · United States, Australia, Brazil and more2Active, not recruitingAstraZenecaJan 31, 2025245
NCT04494425Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaMar 18, 2024866
NCT04482309Pancreatic Neoplasms · United States, Australia, Belgium and more2Active, not recruitingAstraZenecaMar 23, 2027477
NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more2Active, not recruitingAstraZenecaMay 4, 2027452
NCT04042701Breast Neoplasms · United States, France, Spain and more1Active, not recruitingDaiichi SankyoJul 21, 2025115
NCT04014075Neoplasm Metastasis · United States, Belgium, Italy and more2CompletedDaiichi SankyoNov 8, 202179
NCT03734029Breast Neoplasms · United States, Austria, Belgium and more3CompletedDaiichi SankyoJan 11, 2022557
NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more2Active, not recruitingAstraZenecaNov 29, 2024243
NCT03523572Breast Neoplasms · United States, Belgium, France and more1CompletedDaiichi SankyoJul 22, 202186
NCT03529110Breast Neoplasms · United States, Australia, Belgium and more3CompletedDaiichi SankyoMay 21, 2021524
NCT03523585Breast Neoplasms · United States, Australia, Belgium and more3CompletedDaiichi SankyoJun 30, 2022608
NCT03505710Carcinoma, Non-Small-Cell Lung · United States, France, Japan and more2TerminatedDaiichi SankyoMay 3, 2021181
NCT03384940Colorectal Neoplasms · United States, Italy, Japan and more2CompletedDaiichi SankyoAug 9, 201986
NCT03383692Neoplasm Metastasis · Japan, Korea, Republic of, Taiwan1CompletedDaiichi SankyoSep 26, 201840
NCT03368196Adenocarcinoma · Taiwan1CompletedDaiichi SankyoSep 14, 201812
NCT03366428Breast Neoplasms · Japan1CompletedDaiichi SankyoDec 5, 201851
NCT03329690Gastrointestinal Neoplasms · Japan, Korea, Republic of2CompletedDaiichi SankyoNov 8, 2019233
NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more2Active, not recruitingAstraZenecaSep 13, 2024528
NCT03248492Breast Neoplasms · United States, Belgium, Canada and more2TerminatedDaiichi SankyoMar 21, 2019253
NCT02564900Neoplasms · United States, Japan1CompletedDaiichi SankyoFeb 1, 2019292

How it is read

Names in the registry

  • “Trastuzumab deruxtecan”, 22 entries
  • “Trastuzumab Deruxtecan”, 10 entries
  • “DS-8201a”, 7 entries
  • “Trastuzumab deruxtecan (DS-8201a)”, 3 entries
  • “T-DXd”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.